Adocia announces that an abstract relative to bi-hormonal treatment ADO09 (M1Pram) has been accepted for a poster presentation at the upcoming 80th Scientific Sessions of the American Diabetes Association® (ADA). The ADA annual meeting will take place from June 12th until 16th, 2020 as the inaugural virtual event. .
The poster presented by Adocia will describe the results of M1Pram combination in Phase 1 on type 1 diabetic patients. The objective of this study was to compare M1Pram formulation with Novolog®, the widely used fast acting insulin Aspart. In this study, M1Pram offered better glycemic control with less insulin consumption and also significant weight loss.
Details of the accepted abstract presented below:
ADA, 80th Scientific Sessions Website: https://professional.diabetes.org/scientific-sessions from June 12th until 16th, 2020
The Virtual Exhibit Hall will open on Friday, June 12 at 11:30 a.m. U.S. CT.
E-Posters will be visible from Saturday, June 13 at 10:00 a.m. U.S. CT.
E-Poster # 2020-LB-7039-Diabetes, ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D). https://ada.apprisor.org/epsSearchADA.cfm
Presenting Author: Dr. Grégory Meiffren
Session: 112-LB in category 12-E Clinical Therapeutics/New Technology—Insulins.